Market Overview - On March 20, US stock indices experienced slight declines, with the Dow Jones down 0.03%, S&P 500 down 0.22%, and Nasdaq down 0.33% [1] - Chinese concept stocks saw a significant drop, with the Nasdaq Golden Dragon China Index falling 3.84%, marking the largest single-day decline since February 25 [2] Company Performance - Plus Therapeutics experienced a dramatic increase of 170.06% in stock price, with a trading volume of 35.8 million shares, following the announcement of its lung cancer treatment receiving "orphan drug" designation from the FDA [2][3] - Pinduoduo's stock rose 3.97% despite a general downturn in Chinese stocks, reporting a total revenue of 393.8361 billion yuan for 2024, a 59% year-on-year increase, and a net profit of 112.435 billion yuan, up 87% [5][6] Financial Results - Nike reported a revenue of $11.269 billion for Q3 of FY2025, a decline of over 9% year-on-year, with a net profit of $794 million, down over 32% [8] - Micron Technology's adjusted revenue for Q2 was $8.05 billion, a 38% year-on-year increase, exceeding analyst expectations [8] Economic Outlook - Jeffrey Gundlach, co-founder of DoubleLine Capital, indicated a 50% to 60% chance of the US economy entering a recession, citing concerns over tariffs and inflation stability [9]

REYOBIQ™ (rhenium Re186 obisbemeda) continues to be under clinical investigation for Leptomeningeal Metastases (LM) and Recurrent Glioblastoma (GBM) HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the U.S. Food and Drug Administration (FDA) has conditionally accepted the Company’s new ...

HOUSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 27, 2025 after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the ...

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company’s common stock will continue to be listed and ...

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company’s common stock will continue to be listed and ...

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and t ...

Core Viewpoint - Plus Therapeutics, Inc. (PSTV) experienced a significant stock increase of 311.4% on March 6 after receiving Orphan Drug Designation (ODD) from the FDA for its lead candidate, rhenium (186Re) obisbemeda, aimed at treating leptomeningeal metastases in lung cancer patients [1][2]. Company Developments - The FDA's ODD supports the development of treatments for rare disorders affecting fewer than 200,000 individuals in the U.S., providing seven years of market exclusivity post-approval, tax credits for clinical studies, and exemptions from certain FDA fees, including a $4.3 million fee in 2025 [2]. - Rhenium (186Re) obisbemeda is a novel injectable radiotherapy designed for targeted high-dose radiation in central nervous system tumors, potentially improving patient outcomes [4]. - PSTV has completed enrollment in the ReSPECT-LM phase I study, assessing the safety and efficacy of rhenium (186Re) obisbemeda in patients with leptomeningeal metastases, and is advancing to phase II and phase I multiple-dose studies [5]. - The company is also evaluating rhenium (186Re) obisbemeda in the phase I/II ReSPECT-GBM study for recurrent glioblastoma and plans to develop it for pediatric brain cancers [6]. Market Performance - Over the past year, PSTV shares have declined by 14.8%, while the industry average decrease was 9.9% [3].

Core Insights - Rhenium (Re) Obisbemeda shows promising safety and efficacy for glioblastoma patients, with a median overall survival of 17 months for those receiving doses greater than 100 Gy, compared to 8 months with standard care [1][7] - The publication of Phase 1 trial results in a high-impact journal validates the clinical program and supports the ongoing ReSPECT-GBM Phase 2 trial [2] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, particularly recurrent glioblastoma and leptomeningeal metastases [9] - The company utilizes advanced platform technologies to enhance patient outcomes through targeted drug delivery and image-guided local beta radiation [9] Clinical Trial Details - The ReSPECT-GBM trial is currently enrolling patients and aims to provide a much-needed treatment option for recurrent glioblastoma, which has limited existing therapies [2][3] - Rhenium (Re) Obisbemeda is being evaluated in clinical trials, including ReSPECT-GBM and ReSPECT-LM, with significant funding support from the National Cancer Institute and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [5] Disease Context - Glioblastoma affects approximately 15,000 patients annually in the U.S. and is characterized by a poor prognosis, with an average life expectancy of less than 24 months [4] - Current treatments for recurrent glioblastoma offer marginal survival benefits and are associated with significant side effects, highlighting the need for more effective therapies [4] Treatment Mechanism - Rhenium (Re) Obisbemeda is a novel injectable radiotherapy designed to deliver high doses of targeted radiation directly to CNS tumors, potentially improving outcomes compared to existing therapies [5] - The treatment utilizes Rhenium-186, which has a short half-life and is effective for both destroying cancerous tissue and real-time imaging [5]

Core Viewpoint - Plus Therapeutics has received Orphan Drug Designation from the FDA for Rhenium (186Re) Obisbemeda, aimed at treating leptomeningeal metastases in lung cancer patients, highlighting the urgent need for new therapies in this underserved area [1][2]. Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, with a pipeline that includes treatments for recurrent glioblastoma and leptomeningeal metastases [6][7]. - The company utilizes advanced platform technologies that combine image-guided local beta radiation and targeted drug delivery approaches to enhance clinical outcomes for patients [6]. Product Development - Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [5]. - The company has completed the ReSPECT-LM Phase 1 single-dose trial, establishing the recommended Phase 2 dose, and is advancing into further clinical trials [3]. Market Context - Leptomeningeal metastases (LM) is a rare but serious complication of cancer, affecting approximately 5% of cancer patients, with a particularly high incidence in lung cancer and breast cancer [4]. - There are currently no FDA-approved therapies specifically for LM patients, emphasizing the critical need for innovative treatments in this area [4]. Regulatory Milestones - The Orphan Drug Designation provides several benefits, including seven years of market exclusivity, tax credits for clinical trials, and exemptions from significant regulatory fees, which can facilitate the development and commercialization of Rhenium (186Re) Obisbemeda [2].

HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said ...